Document Detail


Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
MedLine Citation:
PMID:  16769916     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Coronary plaque progression and instability are associated with expansive remodeling of the arterial wall. However, the remodeling response during plaque-stabilizing therapy and its relationship to markers of lipid metabolism and inflammation are incompletely understood. METHODS AND RESULTS: Serial intravascular ultrasound (IVUS) data from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial were obtained during 18 months of intensive versus moderate lipid-lowering therapy. In a subgroup of 210 patients, focal coronary lesions with mild luminal narrowing were identified. Lumen area, external elastic membrane (EEM) area, and plaque area were determined at the lesion and proximal reference sites at baseline and during follow-up. The remodeling ratio (RR) was calculated by dividing the lesion EEM area by the reference EEM area. The relationship between the change in remodeling, change in plaque area, lipid profile, and inflammatory markers was examined. At the lesion site, a progression in plaque area (8.9+/-25.7%) and a decrease in the RR (-3.0+/-11.2%) occurred during follow-up. In multivariable analyses, the percentage change in plaque area (P<0.0001), baseline RR (P<0.0001), baseline lesion lumen area (0.019), logarithmic value of the change in high-sensitivity C-reactive protein (P=0.027), and hypertension at baseline (P=0.014) showed a significant, direct relation with the RR at follow-up. Lesion location in the right coronary artery (P=0.006), percentage change in triglyceride levels (P=0.049), and age (P=0.037) demonstrated a significant, inverse relation with the RR at follow-up. Changes in LDL cholesterol, HDL cholesterol, and treatment group demonstrated no significant associations. CONCLUSIONS: Constrictive remodeling of the arterial wall was observed during plaque-stabilizing therapy with statin medications and appears related to their antiinflammatory effects.
Authors:
Paul Schoenhagen; E Murat Tuzcu; Carolyn Apperson-Hansen; Chaohui Wang; Kathy Wolski; Songhua Lin; Ilke Sipahi; Stephen J Nicholls; William A Magyar; Aaron Loyd; Tammy Churchill; Tim Crowe; Steven E Nissen
Related Documents :
16218486 - Bisphosphonates and atherosclerosis: why?
12635466 - Correlation of lipoprotein(a) levels and myocardial stress thallium scintigraphy patter...
1555216 - Relationship between serum total cholesterol, infarct size, and early clinical outcome ...
16297766 - Apolipoprotein a-i mimetic peptides: potential role in atherosclerosis management.
3031936 - Immunocytochemical investigation of acth-cells and vasopressin in the pituitaries of hu...
14768926 - Resuscitation after cardiac surgery: are we ageist?
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-06-12
Journal Detail:
Title:  Circulation     Volume:  113     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-07-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2826-34     Citation Subset:  AIM; IM    
Affiliation:
FAHA, Department of Cardiovascular Medicine, Cardiovascular Imaging, The Cleveland Clinic Foundation, HB-6, 9500 Euclid Ave, Cleveland OH 44195, USA. schoenp1@ccf.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Physiological / drug effects
Adult
Aged
C-Reactive Protein / analysis
Cholesterol / blood
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Coronary Angiography
Coronary Artery Disease / etiology,  physiopathology*
Coronary Vessels / physiopathology*,  ultrasonography
Female
Follow-Up Studies
Heart Catheterization
Heptanoic Acids / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / blood,  complications,  drug therapy*,  physiopathology
Male
Middle Aged
Models, Cardiovascular
Pravastatin / therapeutic use*
Prospective Studies
Pyrroles / therapeutic use*
Risk Factors
Single-Blind Method
Triglycerides / blood
Ultrasonography, Interventional*
Vasculitis / etiology,  physiopathology
Grant Support
ID/Acronym/Agency:
M01 RR-018390/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin; 57-88-5/Cholesterol; 81093-37-0/Pravastatin; 9007-41-4/C-Reactive Protein
Comments/Corrections
Comment In:
Circulation. 2006 Jun 20;113(24):2787-9   [PMID:  16785350 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cognitive outcomes in elderly high-risk patients after off-pump versus conventional coronary artery ...
Next Document:  Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the m...